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Abstract: The reduction in infectious disease morbidity and mortality may be attributed to a variety
of factors; however, improved sanitation and public health, and the introduction of vaccines and
antibiotics are among the most significant. The development of antimicrobial resistance (AMR) in
bacterial pathogens is an expected consequence of evolutionary adaptation to these noxious agents
and the widespread use of these drugs has significantly sped up this process. Infections caused by
multidrug resistant pathogens are directly associated with worse clinical outcomes, longer hospital
stays, excess mortality in the affected patients and an increasing burden and costs on the healthcare
infrastructure. The Sustainable Development Goals (SDGs) were published in 2015 by the United
Nations to serve as a global blueprint for a better, more equitable, more sustainable life on our
planet. The SDGs contextualize AMR as a global public health and societal issue; in addition, the
continuing emergence of AMR may limit the attainment on many SDGs. The aim of this mini-review
is to provide insight on the interface between attainment of SDGs and the clinical problem of drug
resistance in bacteria.
Keywords: antibiotics; antibiotic resistance; MDR; Sustainable Development Goals; SDGs; poverty;
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1. Introduction
Since the occurrence of the so-called epidemiological transition, infectious diseases
and pandemics—which have previously decimated the population—have started to re-
cede, while the life-expectancy of people around the world has increased significantly [1];
although HIV/AIDS, tuberculosis (caused by the bacterium Mycobacterium tuberculosis),
diarrheal illness and neglected tropical diseases (NTDs) were still major causes of suffering
in developing countries, for a short while, it seems that humanity have finally conquered
infectious diseases [2]. Consequently, the structure of the disease burden has shifted con-
siderably to civilizational illnesses, with cardiovascular illnesses, cancer and degenerative
diseases becoming the leading causes of death [3]. The reduction in infectious disease
morbidity and mortality may be attributed to a variety of factors; however, improved
sanitation and public health, the introduction of vaccines and antibiotics are among the
most significant [4]. The discovery and subsequent clinical use of antibiotics may be
considered as one of the game-changing achievements in medicine, revolutionizing the
care of patients, who would have previously succumbed to the onslaught of common or
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deadly bacterial infections, including (in decreasing incidence) respiratory tract infections,
gastro-intestinal infections, urinary tract infections, skin and soft tissue infections, bac-
teremia and others [5,6]. Since the 1950s, antibiotics have saved millions of lives (both
immunocompetent and immunocompromised patients) and they have allowed for the
development of complex medical interventions and specialties, which would not have
been previously possible [7]. However, the emergence of bacteria resistant to these drugs
has proven to be one of the most serious concerns of the millennia.
The development of antimicrobial resistance (AMR) in bacterial pathogens is an ex-
pected consequence of evolutionary adaptation to these noxious agents [8]; nonetheless,
the widespread use of these drugs has significantly sped up this process [9]. Bacteria
can evade the effects of antibiotics in a multitude of ways, including the production of
degrading enzymes (e.g., β-lactamases), adaptation to alternative metabolic pathways
(e.g., folic acid metabolism), target alteration (e.g., modifications in ribosomal subunits or
the topoisomerase enzymes), deceased uptake of the drugs (e.g., outer membrane protein
mutants), over-expression of efflux pumps or by the production of a protective exopolysac-
charide matrix or biofilm [10,11]. The susceptibility of these bacterial pathogens is assessed
in clinical microbiology laboratories using conventional/phenotypic (e.g., disk diffusion,
E-tests, broth microdilution, automated systems) and genotypic tests (i.e., identification of
the carriage of resistance-determinants) [12–14]. Multidrug-resistant (MDR) bacteria mi-
croorganisms can withstand previously lethal doses of structurally and pharmacologically
distinct antibiotic groups and persist in vivo: MDR is usually defined as bacteria resistant to
three of more different antibiotic groups; these extensively drug-resistant (XDR) pathogens
are only susceptible to two remaining agents, while pandrug-resistant (PDR; or totally-
drug resistant, TDR) bacteria show non-susceptibility to all relevant antibiotics [15,16]. The
increasing number of reports in the literature regarding PDR bacteria is the clinical practice
in concerning for everyone [17,18]. Based on their overall clinical impact and significance,
the so-called “ESKAPE” pathogens (E: Enterococcus faecium, S: Staphylococcus aureus or
recently Stenotrophomonas maltophilia, K: Klebsiella pneumoniae or recently C: Clostridioides
difficile, A: Acinetobacter baumannii, P: Pseudomonas aeruginosa, E: Enterobacter spp., or re-
cently Enterobacteriaceae) receive the most attention, both from public health authorities
and from drug development agencies [19]. The Centers for Disease Control and Prevention
(CDC) in the US also published a classification of the most concerning AMR threats, where
they categorized carbapenem-resistant P. aeruginosa and A. baumannii, C. difficile, MDR
Neisseria gonorrhoeae and carbapenem- and cephalosporin-resistant Enterobacteriaceae as
“urgent” threats [20]. The latter has been further highlighted by the Organization for
Economic Co-operation and Development (OECD) report, calling attention to the global
spread of carbapenem-resistance [21]. In 2017, the World Health Organization (WHO) has
also put forth a list of “priority” pathogens, to serve as a guide and to prioritize antimi-
crobial research and development (R&D) to various Gram-negative bacteria (including
non-fermenters and members of the Enterobacteriaceae), posing as particular threats due
to their pathogenic potential and transmissibility (e.g., in nosocomial environments or
nursing homes) [22].
2. Clinical Significance and Driving Forces behind AMR
As previously stated, microorganisms possess a plethora of mechanisms—which are
intrinsic to the bacterial genus or acquired from exogenous sources (encoded by antibiotic-
resistance genes (ARGs) to enhance their survival [23,24]. The emergence and spread of
ARGs may be mediated by spontaneous mutations and subsequent vertical transmission
(i.e. the progeny cells possess the resistance determinant originally “developed” by the
original bacterial cells and via inter- and intra-species horizontal gene transfer (HGT);
the significance of the latter is much higher, as many different resistance-determinants
may reside on various mobile genetic elements (plasmids, transposons and integrons)
with the ability to spread worldwide and among different bacterial genera [25,26]. The
importance of HGT in AMR was highlighted by the rapid global spread of extended-
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spectrum β-lactamases (ESBLs) in Enterobacteriaceae [27]. More recently, the emergence
and spread of carbapenemases in Gram-negative has been identified as a critical public
health issue (at least partly owing to their extensive use for the treatment of infections
caused by ESBLs); while chromosomal carbapenemases were described previously, their
detection on mobile genetic elements allowed for their widespread dissemination (with
the New Delhi metallo-β-lactamase 1 (NDM-1, first detected in India) being a pivotal
example) [28]. Based on their substrate and inhibitor-profiles, carbapenemases may be
differentiated via the Ambler-classification as serine-type (Class A: KPC (K. pneumoniae
carbapenemase), Class D: OXA (oxacillinase)) and metallo-β-lactamases (Class B: IMP
(imipenemase), VIM (Verona integron-borne metallo-β-lactamase) and NDM) [29,30]. Sub-
sequently, carbapenem-resistance has forced the hand of clinicians around the globe to
utilize polymyxins as last-resort drugs in resistant infections, leading to the description
of the Mobilized Colistin Resistance (MCR-1, first detected in China) gene, signaling the
emergence of plasmid-borne resistance to last-resort antibiotics [31,32].
Two phenomena have been identified as the main driving forces behind the clinical
problem of antibacterial resistance in human medicine: on one hand, the imprudent use of
these agents (including overuse (administration of antibiotics in inappropriate indications)
and misuse (administration of antibiotics in inappropriate doses and durations)), which
facilitates the development of resistance in bacteria (this is why these drugs are often
termed “social medicines”, because the misuse by one person affects the efficacy of these
drugs for society as a whole) [33–35]; on the other hand, pharmaceutical companies are
turning away from the marketing authorization of novel antimicrobial drugs, due to
the difficulties in drug development, the lack of returning financial investments and
the inevitable emergence of resistant strains [36]. This is exemplified by the fact that
no new broad-spectrum agent with a novel mechanism of action received marketing
authorization since the introduction of the fluoroquinolones in the 1980s [37]. Unavailability
of primary care (a good indication of a country’s healthcare system), poor public health
conditions (corresponding to high incidence of infectious diseases), over-the-counter sales
of antimicrobials and the lack of health literacy in patients, these medications (especially if
they were obtained without a prescription) are all facilitators of AMR [38]. In a continent-
wide survey sequestered by the European Commission in 2018, the Special Eurobarometer
Report 478 has found that 32% of respondents have taken antibiotics per os in the last
12 months (showing an increasing prevalence in a gradient of west-to-east and north-to-
south throughout the continent); overall, 7% of antibiotics were taken without a prescription
(including non-prescription sales from pharmacies, leftover drugs or antibiotics received
from friends/family). Symptoms and inappropriate conditions, such as a cold, flu or sore
throat were reported as the reason for taking antibiotics in almost 40% of cases; in addition,
28% of respondents in the EU thinks that antibiotics are effective against the cold, while
48% believe that these drugs are useful in viral infections [39].
Self-medication with antibiotics (SMA) is defined as the use of these agents on the
basis of the individual’s symptoms (without any consultation with a physician or a diag-
nosis), with the aim of alleviating these complaints [40]. The prevalence of SMA has been
reported to be between 7.3–81.3% in low- and middle-income countries (LMIC) and 1–66%
in high-income countries, based on two recently published scoping reviews [34,41]. In
both studies, avoiding losing working days and employment was reported as one of the
main reasons for SMA. In both geographical regions, the most commonly taken drugs for
SMA are β-lactam antibiotics (i.e., amoxicillin, ampicillin), however, there are pronounced
differences seen in the sources and reasons for SMA [34,41]. In developed countries, the
main source of these drugs were leftover antibiotics, family members/friends, internet
shops and veterinary pharmacies (i.e., non-prescription sales through community phar-
macies are less common), while in many developed countries, antibiotics are available
over-the-counter in pharmacies and from informal healthcare providers. Unsurprisingly,
SMA is more commonly seen in developed countries, where this is usually coupled with the
unavailability of physicians [34,41]. In the US, SMA is frequent in immigrants and people
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without health insurance [41]. Healthcare professionals (HCPs), including medical doctors,
dentists, pharmacists and prescribing nurses have all pivotal roles as “gate-keepers” en-
suring that these medicines are only used when necessary, while non-prescribing HCPs
may also have roles in patient education [42]. In fact, based on the estimations of the
European Surveillance of Antimicrobial Consumption Network (ESAC-Net) and the CDC,
the majority of antibiotic use is unnecessary in some illnesses managed in the primary care
settings (Table 1) [43]. For some infections (e.g., urinary tract infections), the presence of
symptoms are good indicator for the need of antibiotic-administration; on the other hand,
upper respiratory tract infections are, for the most part, of viral origin (i.e., influenza virus,
parainfluenza virus, rhinovirus, respiratory syncytial virus, adenovirus), where antibiotics
should not be administered without the clarification of the bacterial etiologies, e.g., with
culture results or rapid tests (like Strep A rapid antigen assay) [44]. For this reason, the
WHO has published a competency framework for all HCPs, defining knowledge-levels
and attitudes to successfully combat AMR in everyday practice [45]. To improve the under-
standing of the general public regarding antibiotics and the dangers of AMR, the WHO
has introduced the World Antibiotic Awareness Week (18–24 of November), while the
European Centers for Disease Prevention and Control (ECDC) introduced the European
Antibiotic Awareness Day (18th of November) [46]. While the continuous surveillance,
policy changes and governmental restrictions had positive effects on the judicious use
of antibiotics in Western countries, the same positive trend cannot be observed in many
developing countries in Asia or Africa [47].
In the recent years, there has been a fundamental understanding that the issue of
AMR needs to be addressed using a One Health approach, which—apart from the use
of these drugs in human medicine—also takes into consideration the considerable use of
antibiotics in animal husbandry, the presence of antimicrobials in food products and in the
environment (e.g., water, sewage from hospitals or animal farms) through anthropogenic
contamination [59,60]. In line with this, the design and implementation of interdisciplinary
interventions need to be done to address AMR-related issues [61]. The majority of global
antibiotic consumption is attributable to their use in animal husbandry (both as preventa-
tive medication and as growth promoters for livestock) and in veterinary medicine (for
companion animals); around 70–80% of antibiotic-consumption is attributed to these in-
dustries [62,63]. Livestock production is an important aspect of many national economies
(in the context of gross domestic product, food, raw materials and agriculture operations).
Previously, the unrestricted use of antimicrobials (e.g., avoparcin) was common with the
aim of maximizing profits, which has led to catastrophic consequences; therefore, prohibi-
tion provisions were devised in many countries to restrict the administration of antibiotics
to cases only when it is medically indicated [64,65].
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Infections caused by MDR pathogens are directly associated with worse clinical out-
comes, longer hospital stays, excess mortality in the affected patients and an increasing bur-
den and cost on the healthcare infrastructure [48,49]; the direct and indirect consequences
of AMR are summarized in Table 2. Many national and international bodies’ estimations
and projections on the incidence and consequences of MDR infections have declared for the
government stakeholders around the globe to take action. According to present-day data,
around 700,000 people die from bacterial infections caused by drug-resistant bacteria [50].
Based on the ECDC, MDR bacteria are responsible for over 400,000 infections and 25,000 ex-
cess deaths annually [51], while the CDC estimated over two million MDR infections
and 23,000 excess deaths per year [52]. Similar projections have been also carried out for
Thailand (25,000 deaths/year) and India (38,000 deaths/year) [53,54]. In the European
Union and European Economic Area alone, there have been over 700,000 MDR infections,
33,110 excess deaths and around 875,000 disability-adjusted life years (DALY) reported
by the Burden of Antimicrobial Resistance Collaborative Group for 2015 [55]. The World
Economic Forum (WEF) has compared the insidious nature of the resistance problem to
that of climate change [56]. The O’Neill Report—sequestered by the UK National Health
Service—projected the worse outcome for humanity and global health, in the context of
AMR: financial costs of 100 billion US dollars and over 10 million excess deaths, associated
with drug resistance by 2050 [57]. The expected mortality rates will impact continents
differently: ~500,000 deaths are expected on the European continents, while a much larger
toll might be seen in Africa (~4 million) and Asia (~4.5 million) [57]. The concern for
antibiotic resistance has been highlighted by the fact that the issue has been discussed by
the United Nations (UN) General Assembly; this was only the fourth time a health-related
issue has even been considered by the UN [58].
In the recent years, there has been a fundamental understanding that the issue of
AMR needs to be addressed using a One Health approach, which—apart from the use
of these drugs in human medicine—also takes into consideration the considerable use of
antibiotics in animal husbandry, the presence of antimicrobials in food products and in the
environment (e.g., water, sewage from hospitals or animal farms) through anthropogenic
contamination [59,60]. In line with this, the design and implementation of interdisciplinary
interventions need to be done to address AMR-related issues [61]. The majority of global
antibiotic consumption is attributable to their use in animal husbandry (both as preventa-
tive medication and as growth promoters for livestock) and in veterinary medicine (for
companion animals); around 70–80% of antibiotic-consumption is attributed to these in-
dustries [62,63]. Livestock production is an important aspect of many national economies
(in the context of gross domestic product, food, raw materials and agriculture operations).
Previously, the unrestricted use of antimicrobials (e.g., avoparcin) was common with the
aim of maximizing profits, which has led to catastrophic consequences; therefore, prohibi-
tion provisions were devised in many countries to restrict the administration of antibiotics
to cases only when it is medically indicated [64,65].
Table 2. Direct and indirect consequences of AMR (antimicrobial resistance).
Direct Indirect/Inability to Perform:
Decreased efficacy of available antimicrobial drugs Complex surgical interventions
The onset of administering Organ transplantation
The recovery rate and quality of life (QoL) of affected
patients decreases Cancer chemotherapy
Healthcare use and length of hospital stay increases Intensitve care
Increased costs for the healthcare infrastructure Neonatology
Decreased trust in medicine and pharmaceuticals
3. Sustainable Development Goals (SDGs), Interface between AMR and SDGs
The Sustainable Development Goals (SDGs) were published in 2015 by the UN within
the program of “2030 Agenda for Sustainable Development” to serve as a global blueprint
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for a better, more equitable, more sustainable life on our planet [66]. The UN Earth Summit
(Rio de Janeiro, 1992) and the UN Millennium Summit (New York, 2000) resulted in the
antecedents of SDGs, the Agenda 21 and the Millennium Development Goals (MDGs),
respectively [67,68]. The SDG initiative includes 17 well-defined goals from the fields
of ecology, climate change, societal issues, economy, education and healthcare—that are
frequently interlinked—with well-defined actions, targets and monitoring criteria to allow
for the evaluation of the progress of these goals (Table 3) [69]. These goals were universally
adopted by all UN member states, with the SDGs being continuously followed-up and
reviewed by High-level Political Forum on Sustainable Development, seating annually.
The deadline for attaining most of the SDGs has been set in the year 2030; however, others
do not have a specific deadline [69].
Unsurprisingly, increasing levels of AMR threaten the attainment of the SDGs as this
phenomenon considerably influences changes in society and healthcare: it can be said
that the SDGs contextualize AMR as a global public health and societal issue [70]. This
may have been worsened by the onset of the global severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) pandemic, which has not only further substantiated societal
inequalities and economic difficulties, but has also led to a considerable increase in an-
tibiotic use worldwide for the treatment of patients; it is not yet known what will be the
long-term repercussions of this pandemic in the context of SDGs [71,72]. Most notably,
the use of antibiotics has increased substantially in intensive care units (therapeutically
and prophylactically) in the management of patients suffering from coronavirus disease
(COVID-19) [73]. Antibiotic consumption in Hungary (before the onset of the pandemic)
may be considered as appropriate from a quantitative standpoint (per capita consumption),
however, qualitatively (characterized by the ratio of broad spectrum/narrow spectrum
agents used), this country performs among the worst in the EU, mostly owing to the high
rate of fluoroquinolone consumption [43]. In addition, a study has highlighted that the
unavailability of general practitioners in various geographical regions of Hungary also
leads to worse antimicrobial use qualitatively [74]. Among other antibiotics, the use of
azithromycin has received substantial attention in COVID-19; while azithromycin has been
known to have potent anti-inflammatory properties in the lungs (this has been described
in patients with cystic fibrosis), some early studies on COVID-patients have also suggested
this antibiotic as a potential treatment option with direct effects on the virus; however, the
clinical evidence on this subject is highly controversial [75–77]. Nevertheless, azithromycin
has been included in many institutional and local treatment protocols (even though un-
necessary use of this drug may also bring forth serious cardiovascular adverse events),
both in Hungary and elsewhere around the world [75–77]. This will inevitably lead to the
selection of resistant mutants in bacteria (e.g., respiratory tract pathogens, atypical bacteria)
where azithromycin has therapeutic relevance, which may hinder appropriate therapy for
future patients [78]. It must also be mentioned that many other antimicrobial agents (e.g.,
hydroxychloroquine, ivermectin) were also proposed in the therapy of COVID-19, which
has led to widespread attempts to procure these drugs by laypeople, going as far as looking
for them in veterinary shops or pharmacies [79].
Among other things, the continuing emergence of AMR may limit the attainment
of Goal 1 (No Poverty) and 2 (Zero Hunger). Due to the increasing global population,
economic growth and developments in consumption habits, food production is expected
to grow by 50–70% in the timeframe between 2010–2030; in parallel, the use of antimicro-
bials in food production (e.g., meat, milk, eggs) is also expected to increase by a similar
margin [80]. This has been already demonstrated by major reports: while the increase in
global antibiotic consumption in human medicine only increased by ~10%, consumption of
these drugs in animal husbandry increased by almost 180% in the “BRICS” conglomerate
countries (Brazil, Russia, India, China, and South Africa), with continuous increasing
trends expected till 2030 [81,82]. Resistant bacteria threaten long-term food security, in
addition, they may lead to the demise of the economic prospects of farmers (see Goal
8: Decent Work and Economic Growth). The same thing may be pointed out for people
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experiencing adverse outcomes after MDR infections, which may affect their opportunities
to find employment and to perform at their workplace. People living in poverty are gener-
ally more vulnerable to infectious diseases and they are at a bigger risk to being affected
by drug- resistant bacteria; these patients often do not have the means to obtain some of
the more expensive medications and this is one of the reasons why self-medication with
antibiotics is so common in regions with less developed infrastructures [83,84]. It may be
said that antibiotic resistance can directly worsen societal inequalities (Goal 1 and Goal 10:
Reduce Inequalities). Conversely, implementation of Goal 6 (Clean Water and Sanitation)
will hopefully curb the need for antibiotics by reducing the prevalence of several infections
(i.e., bacteria affecting the gastro-intestinal tract), because as many as 200 diseases may be
transmitted by contaminated water, and it may also reduce the spread of MDR (e.g., from
hospitals or animal farms) to the environment.
Table 3. The list of UN Sustainable Development Goals (2015–2030) *.
Goal 1: No Poverty
Goal 2: Zero Hunger
Goal 3: Good Health and Well-Being
Goal 4: Quality Education
Goal 5: Gender equality
Goal 6: Clean Water in Sanitation
Goal 7: Affordable and Clean Energy
Goal 8: Decent Work and Economic Growth
Goal 9: Industry, Innovation and Infrastructure
Goal 10: Reduced Inequalities
Goal 11: Sustainable Cities and Communities
Goal 12: Responsible Consumption and Production
Goal 13: Climate Action
Goal 14: Live Below Water
Goal 15: Life on Land
Goal 16: Peace, Justice and Strong Institutions
Goal 17: Partnership for the Goals
* The goals deemed relevant by the authors and discussed in the context of AMR are presented in boldface.
The relationship between AMR and worsening climate change is a discreet, but an
important one, nevertheless, Goal 13 (Climate Action). In fact, in the report by the WEF, the
similarities of climate change and AMR are shown as being insidious, inter-disciplinary
and urgent problems for humanity [56]. Changes in the global climate will undoubtedly
result in alterations in the diversity and complexity of microbial populations around the
world; although the emergence of novel bacterial diseases is unlikely, the number of people
at risk for many of these infections will undoubtedly increase, including vector-borne
and zoonotic pathogens, and illnesses associated with food [85,86]. A 1 ◦C increase in
environmental temperatures may be responsible to an increase of 5–10% in the number of
foodborne salmonellosis cases, leading to substantial healthcare and economic costs [87].
It has also been described that increasing temperatures may favor the selection of resis-
tant isolates [88]. Antibiotics should be considered important hallmarks of present-day
medicine; thus, it is unsurprising that the Goal 3 (Good Health and Well-Being for All at
All Ages) will never be achieved if the disadvantageous developments in resistance and
the associated excess death toll are not addressed. Goal 12 (Responsible Consumption and
Production) may also be relevant from the standpoint of facilitating prudent antibiotic
use and antimicrobial stewardship; on the other hand, it is also in the best interest of gov-
ernmental and supra-governmental organizations to advance public–private partnerships
with pharmaceutical companies and biotechnological firms interested in getting involved
in antimicrobial research [89,90]. As resistant bacterial isolates (and AMR in general) do
not respect borders, the long-term management of resistance may only be successful with
the full and continuous collaboration of all global stakeholders and countries (Goal 17:
Partnership for the Goals), which is also an intrinsic requirement for the success of the
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SDGs. In addition to the many international declarations (listed in Section 2), in 2017,
health ministers of the G20 countries have made a historic declaration to fight AMR on a
global scale in a three-pronged approach (including conservation, responsible access and
antimicrobial innovation) [91].
4. Concluding Remarks
By the beginning of the 21st century, it has become painfully clear that AMR has
become one of the major issues in human medicine. Previously, we have highlighted the
multilateral and inter-disciplinary interface between SDGs and AMR. To monitor the impact
of antibiotic resistance and to track the progress of specific interventions—in the context
of SDGs—an important issue that needs to be addressed is the development of a specific
indicator for AMR, or for the hindrance AMR causes in the attainment of SDGs [69]. As
previously mentioned, most of the SDGs have clearly-defined performance indicators and
specific actions to attain the set goals. Some suggest that ensuring universal health coverage
globally would widen the scope of visibility for sustainable development [92]. The more one
assesses the importance of having functional primary healthcare and effective antibiotics
available, the inter-relatedness of resistance and the SDGs becomes more apparent [93];
these common points should be highlighted for government stakeholders to facilitate the
act of taking on the fight against AMR into national agendas.
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